Astal Laboratories Declares Unaudited Q1 FY27 Financial Results

Astal Laboratories Ltd announced the outcome of its Board Meeting held on August 14, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company operates in a single business segment: Manufacturing and Trading of Active Pharmaceutical Ingredients (Bulk Drugs). The financial results were reviewed by the Audit Committee and approved by the Board. The company also noted it has one material wholly-owned subsidiary.